PDC*line Pharma is a Belgian-French a clinical-stage biotech startup developing a new class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line (PDC*line) loaded with peptides derived from target tumour antigens. Founded in 2014 as a spin-off of the French Blood Bank, this startup comprises a team of skilled professionals based in Grenoble (France) and Liège (Belgium).
PDC*line Pharma focuses on lung cancer with a new candidate in phase 1b/2 clinical trial and neoantigens. The objectives of phase I/II study are to assess the safety, tolerability, immunogenicity and preliminary clinical activity of the drug candidate, PDC*lung01.